Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells

Oncotarget

Volumn 5, Issue 23, 2014, Pages 11886-11896

  Yang, Yang ^a,b,c   Su, Dan ^a   Zhao, Lin ^c   Zhang, Dan ^a   Xu, Jiaying ^c   Wan, Jianmei ^c   Fan, Saijun ^c,d   Chen, Ming ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Zhejiang Key Laboratory of Pharmaceutical Technology   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Akt mTOR; Apoptosis; Autophagy; G0 G1 arrest; Lactate dehydrogenase A; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLYCOGEN SYNTHASE KINASE 3BETA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; OXAMIC ACID; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ISOENZYME; LACTATE DEHYDROGENASE 5;

A549 CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; CELL PROLIFERATION; DRUG EFFECTS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; OXAMIC ACID;

EID: 84920006718     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2620     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-271.
3. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-1033.
4. Tennant DA, Duran RV and Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010; 10(4):267-277.
5. Hirschhaeuser F, Sattler UG and Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011; 71(22):6921-6925.
6. Doherty JR and Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123(9):3685-3692.
7. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC and Harris AL. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003; 89(5):877-885.
8. Fantin VR, St-Pierre J and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006; 9(6):425-434.
9. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G and Harris AL. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011; 17(14):4892-4900.
10. Rong Y, Wu W, Ni X, Kuang T, Jin D, Wang D and Lou W. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013; 34(3):1523-1530.
11. Yao F, Zhao T, Zhong C, Zhu J and Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2013; 34(1):25-31.
12. Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J, Zhu Z, Gao Y and Xie K. A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer. Clin Cancer Res. 2014; 20(16):4370-4380.
13. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang CV. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010; 107(5):2037-2042.
14. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP and Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther. 2009; 8(3):626-635.
15. Wang ZY, Loo TY, Shen JG, Wang N, Wang DM, Yang DP, Mo SL, Guan XY and Chen JP. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res Treat. 2012; 131(3):791-800.
16. Fiume L, Manerba M, Vettraino M and Di Stefano G. Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines. Pharmacology. 2010; 86(3):157-162.
17. Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP and Huang G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J. 2012; 279(20):3898-3910.
18. Zhai X, Yang Y, Wan J, Zhu R and Wu Y. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 2013; 30(6):2983-2991.
19. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ and Giovannetti E. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer. 2014; 110(1):172-182.
20. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP and Tan M. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010; 9:33.
21. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE and Tan M. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 2011; 71(13):4585-4597.
22. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, Signoretti S, Billiard J, Duffy KJ, Grant A, Wang X, Lorkiewicz PK, Schatzman S, Bousamra M, 2nd, Lane AN, Higashi RM, et al. Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014; 19(5):795-809.
23. Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8):535-546.
24. Novoa WB, Winer AD, Glaid AJ and Schwert GW. Lactic dehydrogenase. V. Inhibition by oxamate and by oxalate. J Biol Chem. 1959; 234(5):1143-1148.
25. Ramanathan A, Wang C and Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005; 102(17):5992-5997.
26. Shapiro GI and Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest. 1999; 104(12):1645-1653.
27. Isono T, Chano T, Kitamura A and Yuasa T. Glucose deprivation induces G2/M transition-arrest and cell death in N-GlcNAc2-modified protein-producing renal carcinoma cells. PLoS One. 2014; 9(5):e96168.
28. Madhok BM, Yeluri S, Perry SL, Hughes TA and Jayne DG. Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer. 2010; 102(12):1746-1752.
29. Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-1274.
30. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J and Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A. 1998; 95(19):11211-11216.
31. Pap M and Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem. 1998; 273(32):19929-19932.
32. Diehl JA, Cheng M, Roussel MF and Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998; 12(22):3499-3511.
33. Hashimoto T, He Z, Ma WY, Schmid PC, Bode AM, Yang CS and Dong Z. Caffeine inhibits cell proliferation by G0/ G1 phase arrest in JB6 cells. Cancer Res. 2004; 64(9):3344-3349.
34. Gatenby RA and Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4(11):891-899.
35. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y and Huang P. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res. 2009; 69(6):2375-2383.
36. Lunt SY and Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-464.
37. Maes H, Rubio N, Garg AD and Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013; 19(7):428-446.
38. Cheong H, Lu C, Lindsten T and Thompson CB. Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol. 2012; 30(7):671-678.
39. Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD and White E. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 2014; 4(8):914-927.
40. Beck JT, Ismail A and Tolomeo C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 2014; 40(8):980-989.
41. An Z, Tassa A, Thomas C, Zhong R, Xiao G, Fotedar R, Tu BP, Klionsky DJ and Levine B. Autophagy is required for G /G quiescence in response to nitrogen starvation in Saccharomyces cerevisiae. Autophagy. 2014; 10(10).
42. Li T, Kung HJ, Mack PC and Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013; 31(8):1039-1049.
43. Sequist LV, Bell DW, Lynch TJ and Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007; 25(5):587-595.
44. Granchi C, Roy S, Giacomelli C, Macchia M, Tuccinardi T, Martinelli A, Lanza M, Betti L, Giannaccini G, Lucacchini A, Funel N, Leon LG, Giovannetti E, Peters GJ, Palchaudhuri R, Calvaresi EC, et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011; 54(6):1599-1612.
45. Shi Y and Pinto BM. Human lactate dehydrogenase a inhibitors: a molecular dynamics investigation. PLoS One. 2014; 9(1):e86365.
46. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB and Sabatini DM. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014; 508(7494):108-112.